Basic structure of QS-21, consisting of a quillaic acid triterpene (black) substituted with a branched trisaccharide (blue) and a linear tetrasaccharide (green), which is in turn connected to an acyl chain (red) via a hydrolytically labile ester. QS-21 is a 65:35 mixture of the Apiose- and the Xylose-substituted variants of above molecule.
QS-21 is a chromatographic purified fraction out of a plant extract used as a vaccine adjuvant. It is derived from the soap bark tree (Quillaja saponaria), which is native of Chile. The crude drug (Quillajae cortex, Quillaia) is extracted and purified form imported bark coming from Chile.
QS-21 has been clinically evaluated as a vaccine adjuvant. As of 2002[update], it had been tested in more than 3000 patients in 60 clinical trials.
Direct, unencapsulated QS-21 is considered toxic. It also causes immediate pain at injection site and, in vitro, causes hemolysis. All of these can be prevented by packaging QS-21 into lipid-based particles, which also have the added advantage of targeting its delivery to phagocytes. It is part of:
AS-01 (also known as AS01E), GSK's adjuvant used in the Shingrix vaccine, the RTS,S vaccine, and the M72/AS01E vaccine. AS-01 consists of QS-21 and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) sealed inside cholestrol-based liposomes.
Army Liposome Formulation Q (ALFQ), MPL and QS-21 sealed inside cholesterol-based liposomes produced by the US Army. Designed to be unencumbered by AS-01 patents, it was created in 2019 by enhancing the existing, MPL-based Army Liposome Formulation (ALF) with QS-21.
Matrix-M, Novavax's adjuvant used in the Novavax COVID-19 vaccine. Matrix-M contains a mixture of soapbark saponins sealed in nanoparticles made of cholesterol and phospholipid; one of these saponins is QS-21.
Immune-stimulating complex (ISCOM) of 1984 and ISCOMATRIX (CSL Limited, 2012), two forerunners to Matrix-M